SoFi CEO enters prepaid forward contract on 1.5 million shares
Assertio Therapeutics, Inc. (NASDAQ:ASRT) stock has reached a 52-week low, trading at $0.65, as investors navigate through a period of market volatility and industry-specific headwinds. According to InvestingPro analysis, the company maintains a solid gross profit margin of 68.61%, despite current challenges. This low point marks a significant drop for the specialty pharmaceutical company, which has been grappling with various challenges over the past year. With a current market capitalization of $61.94 million, the stock appears undervalued according to InvestingPro Fair Value metrics. The 1-year change data for the company, formerly known as Depomed , reflects a substantial decline of -31.77%, underscoring the downward pressure on the stock and the broader concerns affecting the sector. Investors are closely monitoring the company’s performance and strategic initiatives as they assess the potential for recovery or further declines in the stock’s value. Notably, analyst price targets range from $1.75 to $3.50, suggesting significant upside potential. For deeper insights and additional ProTips about ASRT, including comprehensive valuation analysis, access the full Pro Research Report on InvestingPro.
In other recent news, Assertio Holdings reported its fourth quarter 2024 earnings, which exceeded revenue expectations with $32.18 million, surpassing the forecasted $28.67 million. The company also reported a narrower-than-expected loss per share of $0.03, compared to the forecasted $0.04. Despite these positive results, H.C. Wainwright adjusted Assertio’s stock price target to $3.50 from $4.00, while maintaining a Buy rating. Assertio’s annual revenues reached approximately $125 million, surpassing initial estimates, but the company’s revenue guidance for 2025 is set between $108 million and $123 million, which is below expectations. Analysts from H.C. Wainwright suggest the conservative outlook may be due to slower sales growth for ROLVEDON and ongoing generic competition impacting INDOCIN. Assertio’s full-year net loss in 2024 was $0.23 per share, more significant than anticipated, with a projected net loss of $0.19 per share for 2025. The company is exploring strategic acquisitions, with its CEO indicating a likelihood of such events occurring.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.